Sentinel lymph node biopsy for melanoma: an important risk-stratification tool

Samuel S Zagarella, Michael Sladden, Catalin Popescu and Michael Bigby
Med J Aust 2015; 202 (2): . || doi: 10.5694/mja14.01569
Published online: 2 February 2015

To the Editor: The article by Gyorki and Henderson1 is misleading and inaccurate. The stated primary outcome of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) was:

  • Samuel S Zagarella1
  • Michael Sladden2
  • Catalin Popescu3
  • Michael Bigby4

  • 1 Concord Hospital, Sydney, NSW.
  • 2 University of Tasmania, Launceston, TAS.
  • 3 Carol Davila University of Medicine and Pharmacy, Bucuresti, Romania.
  • 4 Beth Israel Deaconess Medical Center, Boston, Mass, USA.


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.